Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals Limited (NEU) has requested an immediate trading halt of its securities on the ASX, pending the release of top line results from its Phase 2 clinical trial for NNZ-2591 in Angelman syndrome. The halt will remain until the market announcement is made or until normal trading resumes on Friday, 9 August 2024. This strategic pause anticipates significant company news that could impact stock performance.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
